ArticleBMJ open gastroenterology2025

MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT).

Camilla Frimor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.